Biden’s Cancer ‘Moonshot’ Contradiction – WSJ

September 14, 2022 6:33 pm ET Photo: AMGEN/via REUTERS President Biden this week gave a speech promoting his Cancer Moonshot initiative and a new government health agency that he says will drive treatment breakthroughs. As usual, he gave no credit to drug makers that are producing game-changing treatments such as Amgen‘s Lumakras for lung cancer. … Read more

Amgen Inc. stock rises Thursday, still underperforms market

Shares of Amgen Inc. AMGN, +0.27% inched 0.27% higher to $245.45 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +0.66% rising 0.66% to 4,006.18 and the Dow Jones Industrial Average DJIA, +0.61% rising 0.61% to 31,774.52. This was the stock’s second consecutive … Read more

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion

Pfizer Inc. PFE -1.18% is in advanced talks to buy Global Blood Therapeutics Inc., GBT 33.03% the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline. Pfizer is aiming to seal a deal for GBT in the … Read more

Starbucks, Uber, CVS to Report Earnings Amid Shrinking Economy

July 30, 2022 10:00 am ET List two articles (2 minutes) CVS Health Starbucks spirit Uber Technologies are among the companies headlining another busy earnings week as investors look for signs of a recession after a second quarter of contraction in the US economy. Also expected to report earnings are Uber ride-hailing rival Lyft Modern … Read more

Drugmakers Hope New Heart Drugs Boost Sales, Revive Market

The once lucrative heart-drug market is now poised to make a comeback, but at the cost of heavy investments in research and deal making. After watching lower-priced generics seize sales of once-highflying blood-pressure, cholesterol and other heart drugs, companies struggled to discover replacements and then win reimbursement for five-figure prices. Drugmakers are now rolling out … Read more

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

When GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. It will mark what is effectively the end of GlaxoSmithKline, diversified pharma conglomerate, and the birth of GSK (ticker: GSK), a rebranded pure-play biopharma. The … Read more

Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market

Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street could put that aside and start the work of moving higher. Mark Newton, head of technical strategy at … Read more

How to Avoid the Biotech Bear Market: Get Some Products Approved

The mere handful of biotechs stocks that are in positive territory this year offer clues as to what investors are looking for. Elias Stein Text size It’s hard to overstate just how poorly biotech stocks have performed this year. Even as investors rushed into defensive healthcare stocks, the SPDR S&P Biotech exchange-traded fund was down … Read more

Stocks for the Recession That May — or May Not — Be Coming

Text size Exelon stock offers a little bit of offense to go with its defense. Dreamstime The yield curve briefly inverted this past week — and that’s a recession signal that is either like Paul Revere’s ride or the boy who cried wolf. The good news: Investors do not need to decide which just yet. … Read more

Why Alphabet, Nvidia, and Others Belong in the Dow Jones Industrials

The Dow Jones Industrial Average, launched in 1896, has trailed the S&P 500 index of late. That could change if Alphabet, which said on Tuesday that it would split its stock 20-1 (cutting shares from about $ 2,900 to $ 145), were to join the Dow. But cases also can be made for Nvidia, Meta … Read more